The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia
Open accessAbstract
Background.: Carbapenem-resistant Enterobacteriaceae (CRE) are associated with considerable mortality. As mechanisms of carbapenem resistance are heterogeneous, it is unclear if mortality differs based on resistance mechanisms. We sought to determine whether CRE resistance mechanism determination is prognostically informative. Methods.: We conducted an observational study comparing 14-day mortality between patients with carbapenemase-producing (CP)-CRE compared with non-CP-CRE bacteremia. Clinical data were collected on all patients. A comprehensive DNA microarray-based assay was performed on all isolates to identify β-lactamase-encoding genes. Results.: There were 83 unique episodes of monomicrobial CRE bacteremia during the study period: 37 (45%) CP-CRE and 46 (55%) non-CP-CRE. The majority of CP-CRE isolates were blaKPC (92%), followed by blaNDM (5%) and blaOXA-48-type (3%). CP-CRE isolates were more likely to have meropenem minimum inhibitory concentrations (MICs) ≥16 µg/mL, while non-CP-CRE isolates were more likely to have meropenem MICs ≤1 µg/mL (P value < .001). A total of 18 (22%) patients died within 14 days, including 12 (32%) in the CP-CRE group and 6 (13%) in the non-CP-CRE group. Adjusting for severity of illness on day 1 of bacteremia, underlying medical conditions, and differences in antibiotic treatment administered, the odds of dying within 14 days were more than 4 times greater for CP-CRE compared with non-CP-CRE bacteremic patients (adjusted odds ratio, 4.92; 95% confidence interval, 1.01–24.81). Conclusion.: Our findings suggest that CP-CRE may be more virulent than non-CP-CRE and are associated with poorer outcomes. This underscores the added importance of delineating underlying resistance mechanisms of CRE to direct antibiotic treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Spread of Carbapenemase-producing Enterobacteriaceae
Nordmann, P., Naas, T., & Poirel, L. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110655 · Cited by 2,378
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis588 · Cited by 1,016
Boucher, H. W., Talbot, G. H., Benjamin, D. K., Bradley, J., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A., Gilbert, D., & for the Infectious Diseases Society of America (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit152 · Cited by 700
Daikos, G. L., Tsaousi, S., Tzouvelekis, L. S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., Stefanou, I., Sypsa, V., Miriagou, V., Nepka, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02166-13 · Cited by 597
Qureshi, Z. A., Paterson, D. L., Potoski, B. A., Kilayko, M. C., Sandovsky, G., Sordillo, E., Polsky, B., Adams-Haduch, J. M., & Doi, Y. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06268-11 · Cited by 559
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E., & Vardakas, K. Z. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.121004 · Cited by 514
Zarkotou, O., Pournaras, S., Tselioti, P., Dragoumanos, V., Pitiriga, V., Ranellou, K., Prekates, A., Themeli-Digalaki, K., & Tsakris, A. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03514.x · Cited by 438
Attributable Mortality Rate for Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Borer, A., Saidel-Odes, L., Riesenberg, K., Eskira, S., Peled, N., Nativ, R., Schlaeffer, F., & Sherf, M. (2009) · Infection Control & Hospital Epidemiology · doi:10.1086/605922 · Cited by 389
Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections
Ben-David, D., Kordevani, R., Keller, N., Tal, I., Marzel, A., Gal-Mor, O., Maor, Y., & Rahav, G. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03478.x · Cited by 353
Cited by
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac268 · Cited by 526
Self-citationZhang, Y., Wang, Q., Yin, Y., Chen, H., Jin, L., Gu, B., Xie, L., Yang, C., Ma, X., Li, H., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01882-17 · Cited by 450
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1478 · Cited by 441
Self-citationPierce, V. M., Simner, P. J., Lonsway, D. R., Roe-Carpenter, D. E., Johnson, J. K., Brasso, W. B., Bobenchik, A. M., Lockett, Z. C., Charnot-Katsikas, A., Ferraro, M. J., et al. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00193-17 · Cited by 405
Self-citationTamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab295 · Cited by 390
Self-citationGlobal Threat of Carbapenem-Resistant Gram-Negative Bacteria
Jean, S.-S., Harnod, D., & Hsueh, P.-R. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.823684 · Cited by 366
van Duin, D., Arias, C. A., Komarow, L., Chen, L., Hanson, B. M., Weston, G., Cober, E., Garner, O. B., Jacob, J. T., Satlin, M. J., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30755-8 · Cited by 337
Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates
Tamma, P. D., & Simner, P. J. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01140-18 · Cited by 293
Self-citationBuchan, B. W., Windham, S., Balada-Llasat, J.-M., Leber, A., Harrington, A., Relich, R., Murphy, C., Dien Bard, J., Naccache, S., Ronen, S., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00135-20 · Cited by 275
Micafungin breakthrough fungemia in patients with hematological disorders
Kimura, M., Araoka, H., Yamamoto, H., Nakamura, S., Nagi, M., Yamagoe, S., Miyazaki, Y., Ogura, S., Mitsuki, T., Yuasa, M., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02183-17 · Cited by 37
Metadata
- Authors
- Tamma, P. D., Goodman, K. E., Harris, A. D., Tekle, T., Roberts, A., Taiwo, A., & Simner, P. J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-12-24
- Volume
- 64
- Issue
- 3
- Pages
- 257-264
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2552392317
- Cited by
- 402
- References
- 20
- FWCI
- 15.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.